Engineered immune cells could unlock kidney transplants for 'Impossible-to-Match' patients

NCT ID NCT06056102

First seen Jan 08, 2026 · Last updated May 12, 2026 · Updated 19 times

Summary

This study tests a new approach using a patient's own modified immune cells (CAR T cells) to lower the risk of rejecting a donated kidney. It is for people with kidney failure who have been on the transplant waiting list for at least a year and have a very high chance of rejecting most donor kidneys. The goal is to see if this treatment is safe and can reduce the immune system's attack on donor kidneys, potentially making a transplant possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital: Transplantation (Site #: 71107)

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NYU Langone Health (Site #: 71177)

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania Medical Center (Site #: 71111)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.